Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The development of antibodies and associated technologies continues to drive high-value deals. We look at recent trends in the field with help from DealForma.
With three decades of experience, over 200 client partnerships and several cell-line development platforms, Aragen Bioscience supports its global biopharma clients with end-to-end biologics development solutions and services.
GV20 Therapeutics’ platform decodes patients’ B cell responses with artificial intelligence to discover novel targets and antibodies simultaneously. Targets and antibodies are validated and de-risked computationally and experimentally.
The Korea Drug Development Fund and its ADCaptain Project are helping to bring novel antibody therapeutics through the development pipeline to patients in need.
Xentria is taking an innovative approach leveraging in vitro and pharmacokinetic models and the power of partnerships to co-develop accessible treatment options for patients with unmet needs.
Bioengineered Probiotic Yeast Medicines are oral, live therapeutics that express and secrete disease-targeting therapeutic molecules in situ for the treatment of gastrointestinal-related diseases. This synthetic biology approach offers advantages over conventional protein biologics and fulfils the dream of oral administration.
Perspix Biotech’s roPROTix platform combines artificial intelligence, robotics, and wet biology in a closed-loop feedback system for the discovery of next-generation multi-targeting biological therapeutics.
Captor Therapeutics is building a singular pipeline of both next-generation bifunctional degraders and molecular glues based on novel E3 ligases, leveraging academic expertise and industry experience in the United States and Europe, while utilizing significant public and private investment.
South Korean biotech Prazer Therapeutics is creating and validating a breakthrough drug discovery and development platform based on targeted protein degradation (TPD) technology to tackle previously undruggable targets in oncology, neuroscience and other therapeutic areas that are not readily addressable with existing TPD approaches.
InduPro is mapping the cell-surface proteome and designing novel binding proteins to bring cell-surface proteins together to manipulate signaling biology across a range of disease-relevant contexts.
By leveraging the body’s natural RNA-delivery pathways, Sixfold Bioscience is developing a platform that uses modified RNA tags to deliver RNA therapies to desired cell types.
With its innovative modular technology platform and fully integrated organizational approach, DiNAQOR AG is progressing the development and delivery of therapies for devastating genetic diseases of the heart, kidney and other organs.
The promise of accessing tissues beyond the liver is driving deals between pioneers in the field of nucleic-acid-based drugs and companies developing delivery platforms.
Bio-Techne combines expertise in exosome technologies with experience in the non-invasive liquid biopsy market to create solutions for companion diagnostic development and translational biomarker assay development services for biopharmaceuticals.
Pennsylvania-based SEED Therapeutics has leveraged the unmatched expertise of its founding team to develop a target-first molecular glue discovery platform.
By combining molecular science and artificial intelligence with years of experience and a world-leading database, Caris Life Sciences aims to revolutionize cancer care and deliver on the promise of precision oncology medicine in partnership with biopharma and industry innovators.
